PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis

Not yet recruiting

Phase Early 1 Results N/A

Summary of Purpose

This will be a randomized double blind placebo-controlled pilot study using a repeated measures design in which participants with acute ischemic stroke and intracranial atherosclerotic disease are randomized to either drug or placebo.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 24 April 2018.

1 Jun 2018 13 Apr 2018 28 Sep 2020 28 Sep 2021 1 Apr 2018 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

Not available

Contacts